What is HC Wainwright’s Forecast for Genmab A/S Q2 Earnings?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Equities research analysts at HC Wainwright lowered their Q2 2026 earnings per share estimates for Genmab A/S in a research note issued to investors on Tuesday, June 23rd. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.46 per share for the quarter, down from their prior forecast of $0.56. HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.16 per share. HC Wainwright also issued estimates for Genmab A/S’s Q3 2026 earnings at $0.41 EPS, Q4 2026 earnings at $0.37 EPS and FY2026 earnings at $1.32 EPS.

Several other research analysts have also weighed in on the company. Truist Financial assumed coverage on Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price target on the stock. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. Wolfe Research assumed coverage on Genmab A/S in a report on Friday, March 27th. They issued an “outperform” rating and a $32.00 target price on the stock. Wells Fargo & Company began coverage on shares of Genmab A/S in a research report on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price target for the company. Finally, Weiss Ratings cut shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Genmab A/S presently has an average rating of “Moderate Buy” and an average target price of $37.93.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $25.86 on Thursday. Genmab A/S has a 12 month low of $20.23 and a 12 month high of $35.43. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87. The stock has a market cap of $16.12 billion, a PE ratio of 19.59, a price-to-earnings-growth ratio of 1.54 and a beta of 0.85. The business has a fifty day simple moving average of $26.35 and a 200-day simple moving average of $28.86.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GMAB. CIBC Private Wealth Group LLC raised its stake in shares of Genmab A/S by 291.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after purchasing an additional 616 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares during the last quarter. V Square Quantitative Management LLC bought a new stake in shares of Genmab A/S in the 1st quarter valued at approximately $34,000. NewEdge Advisors LLC increased its holdings in Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after buying an additional 1,143 shares during the last quarter. Finally, Brown Brothers Harriman & Co. increased its holdings in Genmab A/S by 143.4% in the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after buying an additional 780 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.